Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Pharmaceuticals

Real-time Estimate Cboe BZX 09:30:44 2024-03-04 am EST 5-day change 1st Jan Change
11.82 USD +0.42% Intraday chart for Roivant Sciences Ltd. +1.47% +4.81%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wolfe Research Initiates Roivant Sciences With Outperform Rating, $17 Price Target MT
Roivant Sciences Swings to Fiscal Q3 Earnings as Net Revenue Rises MT
Transcript : Roivant Sciences Ltd., Q3 2024 Earnings Call, Feb 13, 2024
Roivant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Stocks Decline Pre-Bell Ahead of Key Inflation Data; Asia Mixed, Europe Down MT
Roivant Sciences Insider Sold Shares Worth $1,058,694, According to a Recent SEC Filing MT
Transcript : Roivant Sciences Ltd. Presents at Guggenheim Healthcare Talks| 6th Annual Biotechnology Conference, Feb-07-2024 02:30 PM
Transcript : Roivant Sciences Ltd. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 02:15 PM
Roivant Sciences Insider Sold Shares Worth $33,150,000, According to a Recent SEC Filing MT
Roivant Sciences Completes Sale of Telavant to Roche MT
Roche Holding AG completed the acquisition of Telavant Holdings, Inc. from Roivant Sciences Ltd. and Pfizer Inc.. CI
Deutsche Bank Initiates Coverage on Roivant Sciences With Buy Rating, $14 Price Target MT
Roche enters obesity drug market with $2.7 bln Carmot deal RE
Transcript : Roivant Sciences Ltd. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-30-2023 11:00 AM
Transcript : Roivant Sciences Ltd. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 12:55 PM
Sector Update: Health Care Stocks Decline Premarket Tuesday MT
Roivant Sciences' Immunovant Reports 'Positive' Initial Data From Phase 1 Study of IMVT-1402 MT
Roivant Sciences, Priovant's Phase 2 Study of Oral Brepocitinib to Treat Lupus Fails to Meet Primary Endpoint MT
Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study RE
Roivant Sciences Ltd. and Priovant Therapeutics, Inc. Announces Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus CI
Transcript : Roivant Sciences Ltd. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-15-2023 01:30 PM
Sector Update: Health Care Stocks Mixed Pre-Bell Monday MT
Transcript : Roivant Sciences Ltd., Q2 2024 Earnings Call, Nov 13, 2023
Roivant Sciences' Fiscal Q2 Net Loss Narrows, Net Revenue Rises MT
Futures Down Pre-Bell as Investors Prepare for Key Economic Data Later This Week; Asia Mixed, Europe Up MT
Chart Roivant Sciences Ltd.
More charts
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
11.77 USD
Average target price
16 USD
Spread / Average Target
+35.94%
Consensus
  1. Stock
  2. Equities
  3. Stock Roivant Sciences Ltd. - Nasdaq
  4. News Roivant Sciences Ltd.
  5. Roivant Sciences, Priovant's Phase 2 Study of Oral Brepocitinib to Treat Lupus Fails to Meet Primary Endpoint
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW